Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3087002
Max Phase: Preclinical
Molecular Formula: C30H55N11O5
Molecular Weight: 649.84
Molecule Type: Small molecule
Associated Items:
ID: ALA3087002
Max Phase: Preclinical
Molecular Formula: C30H55N11O5
Molecular Weight: 649.84
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCC(=O)N[C@@H](C)/C=C/C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)/C=C/C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
Standard InChI: InChI=1S/C30H55N11O5/c1-4-5-6-7-8-13-24(42)38-20(2)14-16-26(44)41-23(12-10-19-37-30(34)35)28(46)39-21(3)15-17-25(43)40-22(27(31)45)11-9-18-36-29(32)33/h14-17,20-23H,4-13,18-19H2,1-3H3,(H2,31,45)(H,38,42)(H,39,46)(H,40,43)(H,41,44)(H4,32,33,36)(H4,34,35,37)/b16-14+,17-15+/t20-,21-,22-,23-/m0/s1
Standard InChI Key: DXRAPWREEXXVMJ-NRQZQHSPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 649.84 | Molecular Weight (Monoisotopic): 649.4388 | AlogP: -0.55 | #Rotatable Bonds: 24 |
Polar Surface Area: 283.29 | Molecular Species: BASE | HBA: 7 | HBD: 11 |
#RO5 Violations: 2 | HBA (Lipinski): 16 | HBD (Lipinski): 14 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 13.05 | CX Basic pKa: 12.34 | CX LogP: -1.35 | CX LogD: -5.85 |
Aromatic Rings: 0 | Heavy Atoms: 46 | QED Weighted: 0.03 | Np Likeness Score: 0.30 |
1. Shankar SS, Benke SN, Nagendra N, Srivastava PL, Thulasiram HV, Gopi HN.. (2013) Self-assembly to function: design, synthesis, and broad spectrum antimicrobial properties of short hybrid E-vinylogous lipopeptides., 56 (21): [PMID:24117107] [10.1021/jm400884w] |
Source(1):